MENU
RGNT
Stock ticker: ASE
PRICE
CHANGE
CAPITALIZATION

RGNT stock forecast, quote, news & analysis

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
RGNT
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for RGNT with price predictions
Oct 21, 2026

Momentum Indicator for RGNT turns negative, indicating new downward trend

RGNT saw its Momentum Indicator move below the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator turned negative. In 12 of the 12 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for RGNT turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 5 similar instances when the indicator turned negative. In 5 of the 5 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

RGNT moved below its 50-day moving average on September 25, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RGNT crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 1 of 1 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

RGNT broke above its upper Bollinger Band on September 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RGNT entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RGNT's RSI Oscillator exited the oversold zone, 8 of 10 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGNT advanced for three days, in 18 of 24 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.363) is normal, around the industry mean (4.952). P/E Ratio (-0.062) is within average values for comparable stocks, (36.644). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (56.876).

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. RGNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.3B. The market cap for tickers in the group ranges from 126 to 151.25B. ISRG holds the highest valuation in this group at 151.25B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 0%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 9%. PLSE experienced the highest price growth at 11%, while BNGO experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -33%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was 5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 53
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 95
Seasonality Score: 16 (-100 ... +100)
Momentum Indicator for RGNT turns negative, indicating new downward trend